Expression Of Androgen Receptor Coregulators In Prostate Cancer: Correlation With Progression In Patients After Endocrine Therapy

Expression of androgen receptor coregulators in prostatecancer: Correlation with progression in patients after Endocrine TherapyObjective To evaluate the expression levels of androgen receptor coregulators in prostate cancer to clarify the significance of these markers as prognostic indicators in patients undergoing endocrine therapy.Methods A series of 116 prostate cancer patients undergoing endocrine therapy as a single treatment was studied. Expression levels of steroid receptor coactivator-1 (SRC1) and silencing mediator for retinoid and thyroid hormone receptors (SMRT) in biopsy or TURP specimens obtained from these 116 patients were measured by immunohistochemical staining.Results SRC-1 expression was significantly associated with several conventional prognostic factors. Univariate analysis identified clinical stage,Gleason sum,pretreatment serum PSA level,SRC-1 expression as significant predictors for prostate-specific antigen (PSA) progression after endocrine therapy. Of these significant factors, SRC-1 expression and clinical stage appeared to be independently related to PSA progression after endocrine therapy by multivariate analysis.Conclusions SRC-1 is a useful independent prognostic factor in prostate cancer undergoing endocrine therapy, for use in addition to clinical stage. Combined evaluation of SRC-1 expression and clinical stage would be particularly useful for further refinement of the system in predicting biochemical outcome for those receiving endocrine therapy.